Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.50 |
| ▸ | RAB9A | P51151 | 9/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.43 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301794 | 0.96 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2NOTUMATAD2 | |
| SCHEMBL345941 | 0.78 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2NOTUMPOLB | |
| SCHEMBL8631839 | 0.78 | RAB9A (0.43) | NPC1RAB9ASMN1; SMN2HPGDPOLB | |
| SCHEMBL209522 | 0.78 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL7223282 | 0.78 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL344372 | 0.78 | NPC1 (0.46) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL3616261 | 0.78 | ALDH1A1 (0.50) | NPC1RAB9ASMN1; SMN2HPGDMEN1 | |
| SCHEMBL8626847 | 0.77 | RAB9A (0.54) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL11643481 | 0.77 | CYP1A2 (0.50) | NPC1RAB9ASMN1; SMN2NOTUMHPGD | |
| SCHEMBL15286968 | 0.77 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2NOTUMNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116457353-A | N-substituted 4- (5-phenyl-1, 3, 4-oxadiazol-2-yl) anilines for the treatment and prophylaxis of hepatitis b virus infections | 豪夫迈·罗氏有限公司 | 2023-07-18 | — | — | CN | claimed |
| US-20180327396-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-11-15 | — | — | US | claimed |
| EP-2928867-B1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2017-08-09 | — | — | EP | claimed |
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-3126359-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2017-02-08 | — | — | EP | claimed |
| US-20160376262-A1 | NOVEL PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-12-29 | — | — | US | claimed |
| US-9409866-B2 | Pyridine-2-amides useful as CB2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20150344429-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-12-03 | — | — | US | claimed |
| EP-2928867-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-10-14 | — | — | EP | claimed |
| WO-2015150440-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | claimed |
| WO-2002023784-A2 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-03-21 | — | — | WO | claimed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | claimed |
| US-5371074-A | Use of saccharin derivatives as proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1994-12-06 | — | — | US | claimed |
| EP-0542372-A1 | 2-Substituted saccharin derivative proteolytic enzyme inhibitors | STERLING WINTHROP INC. (US) | 1993-05-19 | — | — | EP | claimed |
| EP-0056157-B1 | USE OF 7-HYDROXY-COUMARIN COMPOUNDS FOR IMPREGNATING PAPER | BAYER AG (DE) | 1985-05-29 | — | — | EP | claimed |
| US-4411946-A | FORGERY-PROOF PAPER | BAYER AKTIENGESELLSCHAFT (DE) | 1983-10-25 | — | — | US | claimed |
| EP-0056157-A1 | Use of 7-hydroxy-coumarin compounds for impregnating paper | BAYER AG (DE) | 1982-07-21 | — | — | EP | claimed |
| US-4294581-A | ANTHRAQUINONE DYES | BASF AKTIENGESELLSCHAFT (DE) | 1981-10-13 | — | — | US | claimed |
| US-4113937-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1978-09-12 | — | — | US | claimed |
| US-4113938-A | OPTICAL BRIGHTENERS | CIBA-GEIGY CORPORATION (US) | 1978-09-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | NPC1 792/4885RAB9A 1736/4885SMN1; SMN2 12/4885 |
| US-20150344429-A1 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS | CNR2, CNR1, GPR52 | NPC1 1531/4885RAB9A 1654/4885SMN1; SMN2 4517/4885 |
| US-20180327396-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | NPC1 1807/4885RAB9A 2378/4885SMN1; SMN2 3107/4885 |
| US-20160376262-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | NPC1 1807/4885RAB9A 2378/4885SMN1; SMN2 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.